H1N1 influenza:
Responding to a pandemic
As H1N1 flu continues to make headlines across the world, GlaxoSmithKline is responding to the flu pandemic.
GSK is investing in the development of vaccines for the influenza A (H1N1) strain of flu and the increased production of the anti-viral Relenza through its own manufacturing facilities and through partnerships with other companies.
More about influenza A (H1N1) at http://us.gsk.com
Announcements
Pandemic (H1N1) 2009 Influenza Update
Together Rx program expands eligibility
1st Quarter 2009 grants and charitable contributions report now available
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment